ZNF177 is a KRAB zinc finger transcription factor involved in RNA polymerase II-dependent transcriptional regulation 1. The gene encodes a DNA-binding protein with C2H2-type zinc finger motifs capable of sequence-specific double-stranded DNA binding and negative regulation of transcription 1. ZNF177 expression is regulated by alternatively spliced transcripts incorporating repetitive elements (Alu, L1, and HERV sequences) in its 5' untranslated region, which increase transcriptional efficiency while decreasing translation efficiency 2. Clinically, ZNF177 hypermethylation is a frequent epigenetic event in multiple cancer types. In colorectal cancer, ZNF177 methylation status as part of a four-gene panel (with NKX6.1, LMX1A, SOX1) predicts poor disease-free and overall survival in stage I-II patients 3. In endometrial carcinoma, ZNF177 promoter methylation shows 92.3% sensitivity and 94.4% specificity for cancer detection 4. ZNF177 methylation also contributes to diagnostic panels for hepatocellular carcinoma 5, breast cancer (AUC=0.9991 with MAST1 and PRDM14) 6, lung cancer 7, and small breast tumors 8. High ZNF177 methylation is associated with improved overall survival in breast cancer patients 6, suggesting potential tumor suppressor functions. These findings establish ZNF177 methylation as a robust biomarker for early cancer diagnosis and prognostication across multiple malignancies.